skip navigation

Skip Nav

Ensayos clínicos

Ensayos clínicos

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Patrocinador(es) del estudio: National Institute of Allergy and Infectious Diseases (NIAID)
Números de identificación: NCT00801697, HVTN 077
  • En curso, con inscripciones cerradas

Propósito del estudio

This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.

Afección:Fase:
Infecciones por el VIH
Fase 1

Detalles del estudio

One of the more promising approaches in the development of a preventive HIV vaccine uses a

DNA plasmid to prime the immune response to an adenoviral vector boost. This primary purpose

of this study is to evaluate the safety, tolerability, and immune response to recombinant

adenoviral serotype 35 (rAd35) and serotype 5 (rAD5) HIV-1 vaccines in Ad-5 naive and Ad-5

exposed HIV-uninfected adults.



This study will last approximately 12 months. Participants will include those who are both

rAD5-naive and rAD5-exposed and will be stratified into one of four groups. Each group will

consist of two arms, one interventional and one control. Participants in Groups 1, 2, and 3

will be rAD5-naive. Participants in Group 4 will be rAD5-exposed.



Participants in Group 1 will receive an injection of rAD35 vaccine or placebo at study entry

and an injection of rAD5 vaccine or placebo at Month 6 with nine follow-up visits through

Month 12. Participants in Groups 2, 3, and 4 will injections of DNA vaccinations or placebo

at study entry and at Months 1 and 2, and an injection of rAD35 vaccine, rAD5 vaccine, or

placebo at Month 6 with twelve follow-up visits though Month 12. A physical, questionnaire,

and counseling will occur at all visits. Blood and urine collection will occur at most

visits. A rectal swab will occur at selected visits. For females, a pregnancy test will

occur at all visits.



Participants will be contacted for safety follow-ups after the injection every year for 5

years. Health and adverse events will be recorded. Participants will not need to return to

the study clinic unless HIV confirmatory testing is needed.One of the more promising approaches in the development of a preventive HIV vaccine uses a

DNA plasmid to prime the immune response to an adenoviral vector boost. This primary purpose

of this study is to evaluate the safety, tolerability, and immune response to recombinant

adenoviral serotype 35 (rAd35) and serotype 5 (rAD5) HIV-1 vaccines in Ad-5 naive and Ad-5

exposed HIV-uninfected adults.



This study will last approximately 12 months. Participants will include those who are both

rAD5-naive and rAD5-exposed and will be stratified into one of four groups. Each group will

consist of two arms, one interventional and one control. Participants in Groups 1, 2, and 3

will be rAD5-naive. Participants in Group 4 will be rAD5-exposed.



Participants in Group 1 will receive an injection of rAD35 vaccine or placebo at study entry

and an injection of rAD5 vaccine or placebo at Month 6 with nine follow-up visits through

Month 12. Participants in Groups 2, 3, and 4 will injections of DNA vaccinations or placebo

at study entry and at Months 1 and 2, and an injection of rAD35 vaccine, rAD5 vaccine, or

placebo at Month 6 with twelve follow-up visits though Month 12. A physical, questionnaire,

and counseling will occur at all visits. Blood and urine collection will occur at most

visits. A rectal swab will occur at selected visits. For females, a pregnancy test will

occur at all visits.



Participants will be contacted for safety follow-ups after the injection every year for 5

years. Health and adverse events will be recorded. Participants will not need to return to

the study clinic unless HIV confirmatory testing is needed.

Criterios de inclusión

    :
    • Good general health
    • Access to a participating HVTN clinical research site and willingness to be followed
    for the duration of the study
    • Assessment of understanding, including understanding of Step Study results
    • Willing to receive HIV test results
    • Willing to discuss HIV infection risks, agree to HIV risk reduction counseling, and
    willing to continue 5 years of annual follow-up contact
    • Willing to commit to maintaining behavior consistent with low risk of HIV exposure
    through the last required protocol visit
    • Considered low risk for HIV infection after clinical staff assessment. More
    information on this criterion can be found in the protocol.
    • Certain laboratory values. More information on this criterion can be found in the
    protocol.
    • Negative Hepatitis B surface antigen
    • Negative anti-Hepatitis C virus antibodies
    • For females, agree to use effective contraception from at least 21 days prior to
    enrollment through the last protocol visit. More information on this criterion can be found in the protocol.

Criterios de exclusión

    :
    • HIV-infected
    • Active drug or alcohol abuse within 12 months prior to study entry
    • History of newly acquired sexually transmitted infections. More information on this
    criterion can be found in the protocol.
    • Experimental vaccines received within 5 years prior to study entry
    • Immunosuppressive medications received within 168 days prior to first vaccination
    • Blood products received within 120 days prior to first vaccination
    • Immunoglobulin received within 60 days prior to first vaccination
    • Live attenuated vaccines received within 30 days prior to first vaccination
    • Investigational research agents received within 30 days prior to first vaccination
    • Intent to participate in another study of an investigational research agent during
    planned duration of the study
    • Any vaccines that not live attenuated vaccines and were received within 14 days prior
    to first vaccination
    • Allergy treatment with antigen injections within 30 days prior to first vaccination
    or scheduled within 14 days after first vaccination
    • Clinically significant medical condition, findings, results, or history with
    implications for current health. More information on this criterion can be found in the protocol.
    • Serious adverse reactions to vaccines
    • Autoimmune disease
    • Immunodeficiency
    • Active Syphilis infection within the past 6 months
    • Asthma. More information on this criterion can be found in the protocol.
    • Diabetes mellitus
    • Thyroidectomy or thyroid disease requiring medication during the last 12 months
    • Hypertension. More information on this criterion can be found in the protocol.
    • Body mass index greater than 35 or 40. More information on this criterion can be
    found in the protocol.
    • Bleeding disorder
    • Malignancy
    • Seizure disorder
    • Asplenia
    • Psychiatric condition that precludes compliance with the protocol
    • Any other clinically significant condition or laboratory abnormality that, in the
    opinion of the investigator, would interfere with the study
    • Pregnant or breastfeeding

Centros de estudio/contactos

Alabama

    Alabama CRS, Birmingham, Alabama, 35294, United States

California

    Bridge HIV CRS, San Francisco, California, 94143, United States

Georgia

    The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, 30030, United States

Massachusetts

    Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, 02115-6110, United States

    Fenway Health (FH) CRS, Boston, Massachusetts, 02215-4302, United States

New York

    New York Blood Center CRS, New York, New York, 10065, United States

    Columbia P&S CRS, New York, New York, 10032-3732, United States

    University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, 14642, United States

Tennessee

    Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, 37232-2582, United States

Washington

    Seattle Vaccine and Prevention CRS, Seattle, Washington, 98109-1024, United States

Actualizado: 16 de junio del 2010

Volver arriba